Summary: The system also enables differentiating between tissue boundaries in bone imaging.
September 5, 2013 - The xSPECT Quant feature on the Symbia Intevo SPECT/CT systems from Siemens Healthcare provides volumetric information from the CT scan for reproducible quantification—a numerical indication of a tumor’s level of metabolic activity.
- Symbia Intevo xSPECT Quant feature allows physicians to apply quantitative information to aid in the assessment whether a patient's course of treatment has regressed, stabilized or grown.
With the precise alignment of SPECT and CT, the xSPECT Quant feature allows physicians to apply quantitative information to aid in the assessment whether a patient's course of treatment has regressed, stabilized or grown—an assessment that is difficult to make with a purely visual assessment of the tumor. The system also enables differentiating between tissue boundaries in bone imaging. With the xSPECT Bone feature, physicians can provide additional support for detection and distinguishing between cancerous lesions and degenerative disorders.
The U.S. Food and Drug Administration (FDA) recently granted 510(k) clearance for Symbia Intevo,1 a xSPECT system or combined single-photon emission computed tomography (SPECT) and computed tomography (CT) system.
In conventional SPECT/CT imaging, the SPECT image has always been reconstructed using SPECT's low-fidelity frame of reference. For this reason, the CT resolution has been downgraded dramatically to the level of SPECT to enable the mechanical fusion of both datasets. Siemens’ new xSPECT modality reconstructs both the SPECT and CT portions of the image using the high CT frame of reference for precise, accurate alignment that facilitates the extraction and deep integration of medically relevant information.
Although Symbia Intevo uses more CT data than ever before, Siemens is still able to limit patient dose by offering combined applications to reduce exposure (CARE). These applications include the CARE Dose4D technique, which can reduce patient CT radiation dose by up to 68%.2
Symbia Intevo also offers applications to improve productivity and patient throughput. For example, Siemens’ AUTOFORM collimator—a standard feature on Symbia Intevo—captures up to 26% more counts, or photons that are generated from radiotracer activity as compared to conventional collimators.2 This increased number of counts potentially reduces image acquisition time for increased patient throughput.
1 Symbia Intevo and xSPECT are not commercially available in all countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
2 Based on competitive literature available at time of publication. Data on file.